Press releases

Regulatory

August 25, 2022

Interim report for the period January 1, 2022 – June 30, 2022

Non Regulatory

August 18, 2022

Invitation to presentation of Vivesto’s Q2 report 2022 on August 25

Non Regulatory

August 15, 2022

Vivesto notes the launch of Apealea® in Germany by Inceptua

Regulatory

July 21, 2022

Vivesto appoints Christer Nordstedt as acting CEO

Regulatory

July 5, 2022

Vivesto winds down its activities in Russia

Regulatory

June 30, 2022

Vivesto appoints Robert Maiorana as acting CFO

Regulatory

June 13, 2022

Vivesto and CEO Francois Martelet have agreed on ending the employment relationship

Regulatory

May 25, 2022

Report from Annual General Meeting in Vivesto AB

Regulatory

May 25, 2022

Interim report for the period January 1, 2022 – March 31, 2022

Non Regulatory

May 18, 2022

Invitation to presentation of Vivesto’s Q1 report 2022 on May 25

Regulatory

April 29, 2022

New number of shares and votes in Vivesto

Regulatory

April 28, 2022

Correction: Vivesto publishes Annual Report for 2021

Regulatory

April 28, 2022

Vivesto publishes Annual Report for 2021

Regulatory

April 25, 2022

Notice of Annual General Meeting in Vivesto AB

Regulatory

April 19, 2022

The Nomination Committee of Vivesto proposes election of new Board members and new Chairman of the Board

Non Regulatory

April 19, 2022

Vivesto signs agreement with leading US CRO to evaluate anti-cancer drug formulations using its proprietary drug delivery platforms

Non Regulatory

April 11, 2022

Vivesto appoints Daniel Tesfa, M.D., PhD as Chief Medical Officer

Regulatory

March 31, 2022

New number of shares and votes in Vivesto

Non Regulatory

March 28, 2022

Oasmia announces completion of name change to Vivesto AB

Regulatory

March 25, 2022

FINAL RESULT OF OASMIA’S RIGHTS ISSUE

Regulatory

March 24, 2022

PRELIMINARY RESULT OF OASMIA’S RIGHTS ISSUE

Non Regulatory

March 21, 2022

Oasmia Signs Manufacturing Agreement with Lonza for Ovarian Cancer Drug Candidate Cantrixil

Non Regulatory

March 17, 2022

Oasmia expands R&D ability with planned laboratory upgrade

Non Regulatory

March 7, 2022

Oasmia to present at Aktiedagen Stockholm on March 14

Non Regulatory

March 7, 2022

Oasmia expands the intellectual property portfolio of its core technology platform in key territories

Regulatory

March 3, 2022

Oasmia announces CFO Fredrik Järrsten to step down later this year

Regulatory

March 3, 2022

OASMIA PUBLISHES PROSPECTUS RELATING TO THE RIGHTS ISSUE

Regulatory

February 24, 2022

Year-end report January 1, 2021 – December 31, 2021

Non Regulatory

February 23, 2022

Update on Progress of SAKK Investigator-Initiated Phase 1b trial of Docetaxel Micellar in Advanced Prostate Cancer

Regulatory

February 21, 2022

Bulletin from Extraordinary General Meeting in Oasmia Pharmaceutical AB

Non Regulatory

February 16, 2022

Invitation to presentation of Oasmia’s year-end report 2021 on February 24

Non Regulatory

January 24, 2022

Oasmia announces progress on the development of its next generation XR-18 drug delivery technology

Regulatory

January 19, 2022

Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB

Non Regulatory

January 19, 2022

Oasmia announces intention to change its name to Vivesto

Regulatory

January 19, 2022

OASMIA RESOLVES ON A FULLY SECURED RIGHTS ISSUE OF APPROXIMATELY SEK 151 MILLION